Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model

Annals of Oncology

Volumn 26, Issue 10, 2015, Pages 2180-2192

  Maia, A R R ^a   De Man, J ^b   Boon, U ^a   Janssen, A ^a   Song, J Y ^a   Omerzu, M ^c   Sterrenburg, J G ^b   Prinsen, M B W ^b   Willemsen Seegers, N ^b   De Roos, J A D M ^b   Van Doornmalen, A M ^b   Uitdehaag, J C M ^b   Kops, G J P L ^c   Jonkers, J ^a,c   Buijsman, R C ^b   Zaman, Guido ^b,d   Medema, R H ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Netherlands Translational Research Center BV   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Chromosome missegregation; Docetaxel; Increased survival; Triple negative breast cancer; TTK Mps1 kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 3146; CHECKPOINT KINASE INHIBITOR; DOCETAXEL; MPI 0497605; MPS BAY 2B; NTRC 0066 0; PACLITAXEL; PROTEIN KINASE TTK; STAUROSPORINE; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; TAXOID; TTK PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CHROMOSOME SEGREGATION; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; MOLECULARLY TARGETED THERAPY; MOUSE; MOUSE MODEL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TRIPLE NEGATIVE BREAST CANCER; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; CHEMICAL STRUCTURE; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; HELA CELL LINE; MORTALITY; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE PROTEINS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; HELA CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; SURVIVAL RATE; TAXOIDS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943736671     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv293     Document Type: Article

References (48)

1. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800.
2. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
3. A'Hern RP, Jamal-Hanjani M, Szasz AM et al. Taxane benefit in breast cancer-a role for grade and chromosomal stability. Nat Rev Clin Oncol 2013; 10: 357-364.
4. Al-Ejeh F, Simpson PT, Sanus JM et al. Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis 2014;3:e100.
5. Daniel J, Coulter J, Woo JH et al. High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. Proc Natl Acad Sci USA 2011; 108:5384-5389.
6. Maire V, Baldeyron C, Richardson M et al. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS One 2013;8: e63712.
7. Liu X, Winey M. The MPS1 family of protein kinases. Ann Rev Biochem 2012; 81:561-585.
8. Sacristan C, Kops GJ. Joined at the hip: kinetochores, microtubules, and spindle assembly checkpoint signaling. Trends Cell Biol 2015; 25: 21-28.
9. Baker DJ, Chen J, van Deursen JM. The mitotic checkpoint in cancer and aging:what have mice taught us?. Curr Opin Cell Biol 2005; 17: 583-589.
10. Kops GJ, Foltz DR, Cleveland DW. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci USA 2004; 101: 8699-8704.
11. Michel L, Diaz-Rodriguez E, Narayan G et al. Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci USA 2004; 101: 4459-4464.
12. Kilpinen S, Ojala K, Kallioniemi O. Analysis of kinase gene expression patterns across 5681 human tissue samples reveals functional genomic taxonomy of the kinome. PLoS One 2010;5: e15068.
13. Landi MT, Dracheva T, Rotunno M et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One 2008;3: e1651.
14. Liang XD, Dai YC, Li ZY et al. Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma. PLoS One 2014;9: e97739.
15. Mills GB, Schmandt R, McGill M et al. Expression of TTK, a novel human protein kinase, is associated with cell proliferation. J Biol Chem 1992; 267:16000-16006.
16. Salvatore G, Nappi TC, Salerno P et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 2007; 67:10148-10158.
17. Slee RB, Grimes BR, Bansal R et al. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715. Mol Cancer Ther 2014; 13: 307-315.
18. Tannous BA, Kerami M, Van der Stoop PM et al. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. J Natl Cancer Inst 2013; 105: 1322-1331.
19. Yuan B, Xu Y, Woo JH et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 2006; 12:405-410.
20. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-627.
21. Carter SL, Eklund AC, Kohane IS et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006; 38: 1043-1048.
22. Sheffer M, Bacolod MD, Zuk O et al. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci USA 2009; 106: 7131-7136.
23. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 2008; 57: 941-950.
24. Colombo R, Caldarelli M, Mennecozzi M et al. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res 2010; 70: 10255-10264.
25. Jemaa M, Galluzzi L, Kepp O et al. Characterization of novel MPS1 inhibitors with preclinical anticancer activity. Cell Death Differ 2013; 20: 1532-1545.
26. Laufer R, Ng G, Liu Y et al. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides. Bioorg Med Chem 2014; 22: 4968-4997.
27. Tardif KD, Rogers A, Cassiano J et al. Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1. Mol Cancer Ther 2011; 10: 2267-2275.
28. Argyriou AA, Koltzenburg M, Polychronopoulos P et al. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008; 66: 218-228.
29. Hilkens PH, Verweij J, Vecht CJ et al. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 1997; 8: 187-190.
30. Uitdehaag JC, de Roos JA, van Doornmalen AM et al. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS One 2014;9: e92146.
31. Rottenberg S, Nygren AO, Pajic M et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 2007; 104: 12117-12122.
32. Nijenhuis W, Vallardi G, Teixeira A et al. Negative feedback at kinetochores underlies a responsive spindle checkpoint signal. Nat Cell Biol 2014; 16:1257-1264.
33. Hewitt L, Tighe A, Santaguida S et al. Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex. J Cell Biol 2010; 190: 25-34.
34. Janssen A, Kops GJ, Medema RH. Elevating the frequency of chromosome missegregation as a strategy to kill tumor cells. Proc Natl Acad Sci USA 2009; 106:19108-19113.
35. Chou TC, Depew KM, Zheng YH et al. Reversal of anticancer multidrug resistance by the ardeemins. Proc Natl Acad Sci USA 1998; 95: 8369-8374.
36. Masuda A, Maeno K, Nakagawa T et al. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 2003; 163:1109-1116.
37. Yamagishi Y, Yang CH, Tanno Y, Watanabe Y. MPS1/Mph1 phosphorylates the kinetochore protein KNL1/Spc7 to recruit SAC components. Nat Cell Biol 2012; 14: 746-752.
38. Maciejowski J, George KA, Terret ME et al. Mps1 directs the assembly of Cdc20 inhibitory complexes during interphase and mitosis to control M phase timing and spindle checkpoint signaling. J Cell Biol 2010; 190: 89-100.
39. Sliedrecht T, Zhang C, Shokat KM, Kops GJ. Chemical genetic inhibition of Mps1 in stable human cell lines reveals novel aspects of Mps1 function in mitosis. PLoS One 2010;5: e10251.
40. Kwiatkowski N, Jelluma N, Filippakopoulos P et al. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol 2010; 6: 359-368.
41. Santaguida S, Tighe A, D'Alise AM et al. Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. J Cell Biol 2010; 190: 73-87.
42. Liu X, Holstege H, van der Gulden H et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 2007; 104: 12111-12116.
43. Jaspers JE, Kersbergen A, Boon U et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 2013; 3:68-81.
44. Solit DB, She Y, Lobo J et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2005; 11:1983-1989.
45. Davis MI, Hunt JP, Herrgard S et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29: 1046-1051.
46. Janssen A, Beerling E, Medema R, van Rheenen J. Intravital FRET imaging of tumor cell viability and mitosis during chemotherapy. PLoS One 2013;8: e64029.
47. Orth JD, Kohler RH, Foijer F et al. Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. Cancer Res 2011; 71: 4608-4616.
48. Zasadil LM, Andersen KA, Yeum D et al. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med 2014;6: 229-243.